2-[(E)-[(2E)-2-(diaminomethylidenehydrazinylidene)-1-phenylethylidene]amino]guanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(E)-[(2E)-2-(diaminomethylidenehydrazinylidene)-1-phenylethylidene]amino]guanidine
• 化学式: C₁₀H₁₄N₈
• 分子量: 246.27
• InChiKey: GUWYZFXTOZCQRE-RPPWDCTQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  154
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
  申请人：Brown R. Truman

  公开号：US20060089316A1

  公开（公告）日：2006-04-27

  Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels in high fructose corn syrop so that the high fructose corn syrup is less likely to induce tumor formation.

  公开了使用各种已知与3-脱氧葡萄糖酮（3DG）或其前体结合的化合物的方法，以减少对肿瘤形成的易感性和/或预防或延迟由3DG及其前体诱导的肿瘤形成。还公开了降低高果糖玉米糖浆中3DG水平的方法，以使高果糖玉米糖浆不太可能诱导肿瘤形成。
• SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL
  申请人：Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

  公开号：EP3006023A1

  公开（公告）日：2016-04-13

  Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

  本文提供了治疗神经精神疾病（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症和双相情感障碍）的方法和组合物。这些方法需要给被诊断为患有神经精神障碍（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症、双相情感障碍等）或有神经精神障碍风险的患者施用苯甲酸、苯甲酸盐和/或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物，并与神经药剂（如抗精神病药、抗精神病药、抗精神病药、抗精神病药）结合使用、苯甲酸、苯甲酸盐或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物的用量足以提高神经药剂的药效。
• Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
  申请人：Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

  公开号：US10039730B2

  公开（公告）日：2018-08-07

  Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

  本文提供了治疗神经精神疾病（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症和双相情感障碍）的方法和组合物。这些方法需要给被诊断为患有神经精神障碍（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症、双相情感障碍等）或有神经精神障碍风险的患者施用苯甲酸、苯甲酸盐和/或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物，并与神经药剂（如抗精神病药、抗精神病药、抗精神病药、抗精神病药）结合使用、其中苯甲酸、苯甲酸盐或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物的用量足以提高神经药剂的药效。
• Devices and compounds for treating arterial restenosis
  申请人：——

  公开号：US20030091611A1

  公开（公告）日：2003-05-15

  Described herein is the use of ADPRT decoy substrates to treat or prevent proliferative disorders. In one example, MIBG is shown to prevent restenosis in damaged vessels. In one embodiment, MIBG is combined with an adhesive agent for localizing the mixture to the site of injury. As a result of this arrangement, MIBG is not systemically released.

  本文描述了使用 ADPRT 诱饵底物治疗或预防增殖性疾病的方法。在一个例子中，MIBG 可防止受损血管的再狭窄。在一个实施方案中，MIBG 与粘合剂结合，用于将混合物定位到损伤部位。由于这种安排，MIBG 不会在全身释放。
• METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF
  申请人：FOX CHASE CANCER CENTER

  公开号：EP1175155A1

  公开（公告）日：2002-01-30